Evidence map›Paper›PMID 37513949›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma.

Liuying Wang, Liuchao Zhang, Shuang Li, Lei Cao, Kang Li, Weiwei Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Implication of protein post translational modifications in gastric cancer.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Liuying WangDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150000, China.
Liuchao ZhangDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150000, China.
Shuang LiDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150000, China.
Lei CaoDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150000, China.
Kang LiDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150000, China.
Weiwei ZhaoMSD R&D (China) Co., Ltd., Beijing 100012, China.
Harbin Medical University · CN

Funding

National Natural Science Foundation of China 81973149
6 · The paper itself

Abstract

backgroundThere have been significant advancements in melanoma therapies. BET inhibitors (BETis) show promise in impairing melanoma growth. However, identifying BETi-sensitive melanoma subtypes is challenging. METHODS AND

resultsWe analyzed 48 melanoma cell lines and 104 patients and identified two acetylation-immune subtypes (ALISs) in the cell lines and three ALISs in the patients. ALIS I, with high

conclusionsThe sensitivity of ALIS I to the BETi JQ-1 may be due to the inhibition of BETi resistance pathways and genes by low

Indexed as

acetylation-immune subtypeBET inhibitorsHAT1histone acetylationimmunotherapyJQ-1KAT2Amelanoma

Identifiers

PMID37513949
PMCPMC10383501
OpenAlexW4385225681

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.